Lemonade Inc vs Smith & Nephew plc — how do they compare? Lemonade Inc trades at $46.46 (market cap $3.63B), while Smith & Nephew plc trades at $27.24 (market cap $11.10B). The key difference: Smith & Nephew plc is far larger — about 3.1× Lemonade Inc's market cap, and Smith & Nephew plc pays a 2.95% dividend while Lemonade Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lemonade Inc for 27 Days and Smith & Nephew plc for 121 Days on average.
| LMND | SNN | |
|---|---|---|
Market Cap | $3.63B | $11.10B |
Volume | 1,544,794 | 1,051,703 |
Sector | Financials | Health |
52-Week High | $96.57 | $37.17 |
52-Week Low | $43.91 | $26.42 |
Typical Hold Time | 27 Days | 121 Days |
Enterprise Value | $3.49B | $14.13B |
Dividend Yield | — | 2.95% |
Signals from Pluang's Aura AI — not financial advice
Lemonade (LMND) trades at $46.91, showing modest daily gains of 0.17%. The stock faces bearish technical signals despite recent earnings beats, with revenue growth accelerating to 32% year-over-year in Q2 2026. The company demonstrates improving fundamentals with gross profit margin at 47.85% and narrowing losses, targeting EBITDA profitability by late 2026. Recent expansion into Alaska and Kentucky markets supports growth trajectory.
Lemonade presents a growth story with improving margins and AI-driven efficiency, but profitability remains elusive. The 33% upside to consensus price target of $67 offers potential reward, though persistent losses and competitive pressures pose significant risks. Investors must weigh the company's expansion momentum against its negative cash flow from operations and high valuation multiples.
Smith+Nephew (SNN) trades at $26.96, near its 52-week low, with bearish technical signals despite recent earnings beats. The company shows strong fundamentals with revenue growth to $6.16B in 2025 and improving profit margins of 10.08%. Recent product launches in trauma care and surgical robotics highlight innovation, but analyst sentiment remains cautious with 65% hold ratings.
Investment outlook is mixed: solid fundamentals and product pipeline offer upside, but technical weakness and analyst skepticism pose near-term risks. Key catalysts include execution on new product adoption and margin expansion, while risks involve competitive pressures and leadership transitions following the CFO's departure.
Trailing returns across standard periods
Latest headlines on both assets
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes.
Read more on LMND →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →